NovoCure Limited (NVCR)
(Real Time Quote from BATS)
$12.11 USD
+0.06 (0.50%)
Updated Apr 19, 2024 01:38 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Brokerage Reports
0 items in cart
NovoCure Limited [NVCR]
Reports for Purchase
Showing records 1 - 20 ( 206 total )
Company: NovoCure Limited
Industry: Medical Services
METIS Passes the Litmus Test, But the Acid Test Comes Later
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: NovoCure Limited
Industry: Medical Services
Company: NovoCure Limited
Industry: Medical Services
INNOVATE-3 Subgroup Data Indicate Efficacy in Earlier Stage Ovarian Cancer Patients
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: NovoCure Limited
Industry: Medical Services
Company: NovoCure Limited
Industry: Medical Services
INNOVATE-3 Innovating in PLD-naïve Ovarian Cancer
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: NovoCure Limited
Industry: Medical Services
4Q23 Recap: Several Large Catalysts on Track For 2024 Though Some Uncertainties Persist
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: NovoCure Limited
Industry: Medical Services
Company: NovoCure Limited
Industry: Medical Services
Preliminary 4Q23 Optune Revenues Indicate Improving Growth Dynamics; 2L NSCLC PMA Submitted
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: NovoCure Limited
Industry: Medical Services
NVCR Looking for Lung to Breathe Life into Revenues
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: NovoCure Limited
Industry: Medical Services
Company: NovoCure Limited
Industry: Medical Services
Pipeline Prioritization and Restructuring Announced; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: NovoCure Limited
Industry: Medical Services
Optimized Entry and Exit Levels for NVCR 112223
Provider: Stock Traders Daily
Analyst: Research Department
Company: NovoCure Limited
Industry: Medical Services
Company: NovoCure Limited
Industry: Medical Services
3Q23 Recap: Strong Optune France Launch; NSCLC PMA Submission Expected 4Q23
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: NovoCure Limited
Industry: Medical Services
Company: NovoCure Limited
Industry: Medical Services
TTFields Fails to INNOVATE-3 in Ovarian Cancer
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: NovoCure Limited
Industry: Medical Services
INNOVATE-3 Did Not Meet Its Primary Endpoint; Downgrading to Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: NovoCure Limited
Industry: Medical Services
Company: NovoCure Limited
Industry: Medical Services
Company: NovoCure Limited
Industry: Medical Services
2Q23 Recap: INNOVATE-3 Top-Line in 3Q23 is the Next Significant Catalyst; Optune Sales Are Beginning to Recover
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E